HFSA/ACC/AHA, et al, (Accessed April 1, 2020), cited as Ref 23 in DOI: 10.1007/s11886-020-01293-2 (Q11017)

From Wikibase.slis.ua.edu
Revision as of 14:16, 22 June 2020 by Admin (talk | contribs) (‎Created claim: Property:P149: HFSA/ACC/AHA, #quickstatements; #temporary_batch_1592835264664)
Jump to navigation Jump to search
Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.
Language Label Description Also known as
English
HFSA/ACC/AHA, et al, (Accessed April 1, 2020), cited as Ref 23 in DOI: 10.1007/s11886-020-01293-2
Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.

    Statements

    title
    HFSA/ACC/AHA Joint Statement addressing concerns re: using RAAS antagonists in COVID-19. (English)
    0 references
    Publication Date
    2020
    0 references
    First Author string
    HFSA/ACC/AHA
    0 references
     

    Sitelinks

    Retrieved from "http://wikibase.slis.ua.edu/w/index.php?title=Item:Q11017&oldid=221695"